Eikonoklastes completes a license to add novel gene therapy for treating neurodegener
 

Eikonoklastes Therapeutics, a preclinical stage biopharmaceutical company, today announced it has completed a license with the University of California San Diego to add a novel gene therapy for the treatment of neurodegenerative diseases.

More...